Efficacy and safety of mizoribine by one single dose administration for patients with rheumatoid arthritis

Internal Medicine

Volumn 49, Issue 20, 2010, Pages 2211-2218

  Ichinose, Kunihiro ^a   Origuchi, Tomoki ^a   Kawashiri, Shin Ya ^a   Iwamoto, Naoki ^a   Fujikawa, Keita ^a   Aramaki, Toshiyuki ^a   Kamachi, Makoto ^a   Arima, Kazuhiko ^a   Tamai, Mami ^a   Nakamura, Hideki ^a   Ida, Hiroaki ^a   Kawakami, Atsushi ^a   Tsukada, Toshiaki ^b   Ueki, Yukitaka ^c   Eguchi, Katsumi ^a  

^a NAGASAKI UNIVERSITY   (Japan)

^b Isahaya Health Insurance General Hospital   (Japan)

^c SASEBO CHUO HOSPITAL   (Japan)

Author keywords

Mizoribine (MZR); Plasma level; Rheumatoid arthritis (RA)

Indexed keywords

BUCILLAMINE; C REACTIVE PROTEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GOLD SALT; METHOTREXATE; MIZORIBINE; PREDNISOLONE; SALAZOSULFAPYRIDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HUMAN; INTERSTITIAL PNEUMONIA; KIDNEY DYSFUNCTION; LUNG DISEASE; MALE; OSTEOPOROSIS; PILOT STUDY; PROTEIN BLOOD LEVEL; RHEUMATOID ARTHRITIS; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; C-REACTIVE PROTEIN; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PILOT PROJECTS; PREDNISOLONE; RIBONUCLEOSIDES; TREATMENT OUTCOME;

EID: 78449302472     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.49.3810     Document Type: Article

References (29)

1. Mizuno K, Tsujino M, Takada M, Hayashi M, Atsumi K. Studies on bredinin. I. Isolation, characterization and biological properties. J Antibiot (Tokyo) 27: 775-782, 1974.
2. Koyama H, Tsuji M. Genetic and biochemical studies on the activation and cytotoxic mechanism of bredinin, a potent inhibitor of purine biosynthesis in mammalian cells. Biochem Pharmacol 32: 3547-3553, 1983.
3. Kusumi T, Tsuda M, Katsunuma T, Yamamura M. Dual inhibitory effect of bredinin. Cell Biochem Funct 7: 201-204, 1989.
4. Hughes SE, Gruber SA. New immunosuppressive drugs in organ transplantation. J Clin Pharmacol 36: 1081-1092, 1996.
5. Inou T, Kusaba R, Takahashi I, et al. Clinical trial of bredinin in renal transplantation. Transplant Proc 13: 315-318, 1981.
6. Takei S. Mizoribine in the treatment of rheumatoid arthritis and juvenile idiopathic arthritis. Pediatr Int 44: 205-209, 2002.
7. Aihara Y, Miyamae T, Ito S, et al. Mizoribine as an effective combined maintenance therapy with prednisolone in child-onset systemic lupus erythematosus. Pediatr Int 44: 199-204, 2002.
8. Yoshioka K, Ohashi Y, Sakai T, et al. A multicenter trial of mizoribine compared with placebo in children with frequently relapsing nephrotic syndrome. Kidney Int 58: 317-324, 2000.
9. Kaneko K, Nagaoka R, Ohtomo Y, Yamashiro Y. Mizoribine for childhood IgA nephropathy. Nephron 83: 376-377, 1999.
10. Kasama T, Wakabayashi K, Odai T, et al. Effects of low-dose mizoribine pulse therapy in combination with methotrexate in rheumatoid arthritis patients with an insufficient response to methotrexate. Mod Rheumatol 19: 395-400, 2009.
11. Horikoshi M, Ito S, Ishikawa M, et al. Efficacy of mizoribine pulse therapy in patients with rheumatoid arthritis who show a reduced or insufficient response to infliximab. Mod Rheumatol 19: 229-234, 2009.
12. Sakai K, Matsuno H, Tsuji H, Sainou H, Yashima S. Synocial fluid and plasma levels of mizoribine in RA patients. Jpn J Inflamm 14: 521-524, 1994 (in Japanese).
13. Tanaka H, Suzuki K, Nakahata T, Tsugawa K, Ito E, Waga S. Mizoribine oral pulse therapy for patients with disease flare of lupus nephritis. Clin Nephrol 60: 390-394, 2003.
14. Sonda K, Takahashi K, Tanabe K, et al. Clinical pharmacokinetic study of mizoribine in renal transplantation patients. Transplant Proc 28: 3643-3648, 1996.
15. Kawasaki Y, Hosoya M, Kobayashi S, et al. Oral mizoribine pulse therapy for patients with steroid-resistant and frequently relapsing steroid-dependent nephrotic syndrome. Nephrol Dial Transplant 20: 2243-2247, 2005.
16. Nishioka Y, Horita Y, Tadokoro M, et al. Changing mizoribine administration from three divided doses to one single dose induced remission of relapsed membranous nephropathy. Nephrol Dial Transplant 21: 2337-2338, 2006.
17. Steinbrocker O, Traeger CH, Batterman RC. Therapeutic criteria in rheumatoid arthritis. J Am Med Assoc 140: 659-662, 1949.
18. Nakamura N, Nishimura K, Nishino J, Fukunaga S, Kochi A, Matsushita T. Single dose mizoribine at 100 or 50 mg/day for rheumatoid arthritis: efficacy and safety profile results of 6-month administration. Mod Rheumatol 17: S112, 2007.
19. Nishimura K. Prevention of joint destruction in rheumatoid arthritis patients receiving combination mizoribine and methotrexate therapy. Pharm Medica 26: 134-135, 2008 (in Japanese).
20. Kuroda T, Hirose S, Tanabe N, et al. Mizoribine therapy for patients with lupus nephritis: the association between peak mizoribine concentration and clinical efficacy. Mod Rheumatol 17: 206-212,2007.
21. Tokuda M, Dobashi H, Hiraishi T, Mitsunaka H, Takahara J, Hirohata M. Effect of mizoribine pulse therapy on the disease activity of rheumatoid arthritis refractory to the treatment with methotrexate. Rheumatology 20: 519-526, 1998 (in Japanese).
22. Kohriyama K, Hiramatsu Y, Aoyama T. Efficacy of combination pulse therapy with methotrexate and mizoribine for patients with rheumatoid arthritis showing escape phenomenon to low-dose methotrexate therapy. Rinsho Riumachi 15: 227-234, 2003 (in Japanese).
23. Murai T, Arai K, Fujisawa J, Kondo N, Hanyu T. Evaluation of combination pulse therapy with methotrexate and mizoribine for patients with methotrexate-resistant rheumatoid arthritis. J Chubu Rheum Assoc 37: 80-81, 2006 (in Japanese).
24. Shida J, Shuto T, Tokito T, et al. Clinical investigation of efficacy by administration of mizoribine once a day for rheumatoid arthritis. Kyushu Riumachi 26: 9-14, 2006 (in Japanese).
25. Tanaka H, Mine T, Tani Y, Chagawa K, Taguchi T. Combination therapy with methotrexate and mizoribine for patients with rheumatoid arthritis. Orthop Traumatol 57: 439-442, 2008 (in Japanese).
26. Takada K, Asada S, Ichikawa Y, et al. Pharmacokinetics of bredinin in renal transplant patients. Eur J Clin Pharmacol 24: 457-461,1983.
27. Katayama A, Uchida K, Goto N, et al. Evaluation of the blood mizoribine concentration during high-dose mizoribine administration (10 mg/kg/day) in the early period after kidney transplantation (Part 2). Ther Res 24: 986-988, 2003 (in Japanese).
28. Tsubouchi Y, Fukuda W, Kawahito Y, et al. A case of lupus nephritis improved after appropriately adjusting the dosage of mizoribine. Mod Rheumatol 18: 91-95, 2008.
29. Study Group of the Ministry of Hearth, Labour and Welfare. Diagnostic and therapeutic manual of rheumatoid arthritis. Diagnostic manual and evidence-based treatment guidelines. Tokyo: Japan Rheumatism Foundation 2004 (in Japanese).